Stock Ratings / Health Care / TIL / insiders

LONA (42) IMA (24) CRBU (43) INMB (45) ⌘ Pro Terminal →

Instil Bio Inc. (TIL) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$6.83 +0.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.82

Instil Bio Inc. (TIL) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY) →

ROARABLE D • SELL / AVOID Cap $46.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.82 (-0.10%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY • 49.7% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-3.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TIL)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (51/100 Composite)

🔍 WHY TIL SCORES 51/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (29% of score)

FRED Regime × Technicals: 11% of 52W Range • RSI-14 at 56.4 (BULLISH MOMENTUM)

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (24% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$6.74-12.3% Next Q

Q2 (-2Q)

Grade D$5.91-1.2% Next Q

Q3 (-1Q)

Grade D$5.84+17% Next Q

Current

Grade D$6.83-1.3% Hist 90D α

Trajectory: D (43) → D (51)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TIL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TIL currently carries a cautious 51/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.96) and Max Pain ($7.17) forces dealer call-delta covering toward $18.49.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TIL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “TIL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 51%NO 49%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

TIL Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (TIL)

No recent open-market Form 4 cluster sales or emergency dumps flagged on TIL. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TIL)

✓Walkthrough of TIL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TIL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.41%▼ DESCENDING CHANNEL

2026-10-30O $6.74H $6.87L $6.51C $6.83VOL 25.2K

RES: $7.53SUP: $5.51SMA50: $6.96SMA200: $7.68

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TIL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TIL Butterfly Map → + Track TIL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TIL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TIL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TIL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TIL)

Health Care Rank #338 of 1016 ⚔️ LONA vs TIL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TIL vs. LONA, IMA, CRBU, INMB)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Instil Bio Inc. (TIL) ranks #338 by composite RQD confidence (51/100, grade D) and #760 by equity capitalization ($46.3M). Within this direct 5-issuer industry benchmark cohort, TIL leads on earnings valuation at N/A trailing P/E, while TIL leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TIL currently leads its immediate peer cohort in composite quantitative strength at 51/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TIL ACTIVE Instil Bio Inc.	D	51/100	—	—	-35.0%	+0.52%	$46.3M	Benchmark Subject
LONA LeonaBio Inc.	D-	42/100	—	—	-35.0%	-1.01%	$46.3M	/lona-vs-til →
IMA ImageneBio Inc.	E	24/100	—	—	-35.0%	-3.57%	$46.0M	/ima-vs-til →
CRBU Caribou Biosciences Inc.	D-	43/100	—	—	-35.0%	-9.07%	$47.7M	/crbu-vs-til →
INMB INmune Bio Inc.	D	45/100	—	—	-35.0%	+4.58%	$44.4M	/inmb-vs-til →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001789769

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Instil Bio Inc. (TIL) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$71.4M, operating cash flow of -$36.6M, and free cash flow of -$36.6M (+34.3% YoY). On the balance sheet, TIL closed FY2025 with $203.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$71.4M	-$36.6M	-$36.6M	$203.5M	—
FY2024 (FY)	2024-12-31	$0	-$74.1M	-$55.7M	-$55.7M	$263.6M	—
FY2023 (FY)	2023-12-31	$0	-$156.1M	-$82.0M	-$82.0M	—	—

3. TIL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TIL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Instil Bio Inc. (NASDAQ: TIL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $6.83 (+0.52% 1D, market cap $46.3M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, TIL ranks #338 in composite RQD confidence.

How does TIL compare to LONA and IMA in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TIL carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LONA (LeonaBio Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $46.3M) and IMA (ImageneBio Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $46.0M). Among the 5-stock peer group, TIL leads on earnings multiple (N/A) while TIL leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TIL?

Per TIL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001789769), Instil Bio Inc. generated $0 in revenue, -$71.4M in net income, and -$36.6M in free cash flow against $203.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TIL trading relative to its 50-day, 200-day, and 52-week technical levels?

TIL last traded at $6.83 (+0.52% on volume of 57,669 shares), positioning the stock -1.87% below its 50-day simple moving average ($6.96) and -11.07% below its 200-day simple moving average ($7.68). Across its 52-week range of $5.56 to $17.61, TIL sits at the 10.5% percentile with a 14-day RSI of 56.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($5.98 to $7.68).

TIL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are TIL insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies TIL leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: TIL RQD Cockpit TIL 12M Forecast TIL Earnings & Move TIL Dividends & DRIP TIL Insiders & 13F TIL Whale Options TIL Profit Sankey TIL News & Why